What changed
$REGN — HOLD 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $3.6B | EPS $9.47 vs $8.90 🟢 | Margin 17.8%
💡 Consensus underestimated Q1 earnings, but the beat was modest (6.4%) and likely priced in post-report. The market may already reflect improved forward estimates, as the price sits near the historical P/E multiple median. There is no evident dislocation between price and fundamentals.
📉 Reward/risk: 1.32:1
🏢 Business Quality: 8/10 - REGN is a leading biotech with strong margins, diversified late-stage pipeline, and a track record of innovation, generating consistent cash flows.
📊 Valuation: fair - Trailing P/E 14.7x aligns with historical median (14.7x) and peers (large biotech range 12-18x).
🔮 Catalyst: Potential catalyst: upward revision cycle post-beat, or pipeline milestones (e.g., Dupixent label expansion, new drug approvals).
📊 Our read: HOLD. Full analysis →
https://stockduty.xyz/s/REGN0623